Imaging in Central Nervous System Drug Discovery
The discovery and development of central nervous system (CNS) drugs is an extremely challenging process requiring large resources, timelines, and associated costs. The high risk of failure leads to high levels of risk. Over the past couple of decades PET imaging has become a central component of the...
Saved in:
| Published in | Seminars in nuclear medicine Vol. 47; no. 1; pp. 89 - 98 |
|---|---|
| Main Authors | , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Elsevier Inc
01.01.2017
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | The discovery and development of central nervous system (CNS) drugs is an extremely challenging process requiring large resources, timelines, and associated costs. The high risk of failure leads to high levels of risk. Over the past couple of decades PET imaging has become a central component of the CNS drug-development process, enabling decision-making in phase I studies, where early discharge of risk provides increased confidence to progress a candidate to more costly later phase testing at the right dose level or alternatively to kill a compound through failure to meet key criteria. The so called “3 pillars” of drug survival, namely; tissue exposure, target engagement, and pharmacologic activity, are particularly well suited for evaluation by PET imaging. This review introduces the process of CNS drug development before considering how PET imaging of the “3 pillars” has advanced to provide valuable tools for decision-making on the critical path of CNS drug development. Finally, we review the advances in PET science of biomarker development and analysis that enable sophisticated drug-development studies in man. |
|---|---|
| AbstractList | The discovery and development of central nervous system (CNS) drugs is an extremely challenging process requiring large resources, timelines, and associated costs. The high risk of failure leads to high levels of risk. Over the past couple of decades PET imaging has become a central component of the CNS drug-development process, enabling decision-making in phase I studies, where early discharge of risk provides increased confidence to progress a candidate to more costly later phase testing at the right dose level or alternatively to kill a compound through failure to meet key criteria. The so called "3 pillars" of drug survival, namely; tissue exposure, target engagement, and pharmacologic activity, are particularly well suited for evaluation by PET imaging. This review introduces the process of CNS drug development before considering how PET imaging of the "3 pillars" has advanced to provide valuable tools for decision-making on the critical path of CNS drug development. Finally, we review the advances in PET science of biomarker development and analysis that enable sophisticated drug-development studies in man.The discovery and development of central nervous system (CNS) drugs is an extremely challenging process requiring large resources, timelines, and associated costs. The high risk of failure leads to high levels of risk. Over the past couple of decades PET imaging has become a central component of the CNS drug-development process, enabling decision-making in phase I studies, where early discharge of risk provides increased confidence to progress a candidate to more costly later phase testing at the right dose level or alternatively to kill a compound through failure to meet key criteria. The so called "3 pillars" of drug survival, namely; tissue exposure, target engagement, and pharmacologic activity, are particularly well suited for evaluation by PET imaging. This review introduces the process of CNS drug development before considering how PET imaging of the "3 pillars" has advanced to provide valuable tools for decision-making on the critical path of CNS drug development. Finally, we review the advances in PET science of biomarker development and analysis that enable sophisticated drug-development studies in man. The discovery and development of central nervous system (CNS) drugs is an extremely challenging process requiring large resources, timelines, and associated costs. The high risk of failure leads to high levels of risk. Over the past couple of decades PET imaging has become a central component of the CNS drug-development process, enabling decision-making in phase I studies, where early discharge of risk provides increased confidence to progress a candidate to more costly later phase testing at the right dose level or alternatively to kill a compound through failure to meet key criteria. The so called “3 pillars” of drug survival, namely; tissue exposure, target engagement, and pharmacologic activity, are particularly well suited for evaluation by PET imaging. This review introduces the process of CNS drug development before considering how PET imaging of the “3 pillars” has advanced to provide valuable tools for decision-making on the critical path of CNS drug development. Finally, we review the advances in PET science of biomarker development and analysis that enable sophisticated drug-development studies in man. |
| Author | Rabiner, Eugenii A. Gunn, Roger N. |
| Author_xml | – sequence: 1 givenname: Roger N. surname: Gunn fullname: Gunn, Roger N. email: roger.gunn@imanova.co.uk organization: Imanova Ltd, London, United Kingdom – sequence: 2 givenname: Eugenii A. surname: Rabiner fullname: Rabiner, Eugenii A. organization: Imanova Ltd, London, United Kingdom |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/27987561$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkUFr3DAQhUVJaDZp_0LxsRc7I8mS5Utou2nTQEgPaaE3oUrjRVtbTiV7Yf99ZTahECjsQQjEm0_vvTknJ2EMSEhBoaIg-OW2SjiE2fYDuooBlRW0FQB9RVZUCFXWkvETsoL8VLK2VWfkPKUtABOiFa_JGWta1QhJVwRuB7PxYVP4UKwxTNH0xT3G3Tin4mGfJhyK6zhvimuf7LjDuH9DTjvTJ3z7dF-QH18-f19_Le--3dyuP96VtlZyKp1QktVolG3rfDqBgLShXMnOmewOTCfAQgNorHTCIWOSc-u4a1DVvOYX5P2B-xjHPzOmSQ_ZAva9CZjNaaoEzdEaDln67kk6_8qF6MfoBxP3-jllFlwdBDaOKUXstPWTmfy45PW9pqCXWvVW_6tVL7VqaHXuMAPUC8DzH0eMfjqMYi5r5zHqZD0Gi85HtJN2oz8GcvUCYnsfvDX9b9xj2o5zDHkZmurENOiHZfHL3qnkAA39mQEf_g84zsNfJYDCPw |
| CitedBy_id | crossref_primary_10_1038_s41380_023_02271_0 crossref_primary_10_1016_j_neuroimage_2022_119620 crossref_primary_10_1155_2020_8838888 crossref_primary_10_1053_j_semnuclmed_2022_08_008 crossref_primary_10_1038_s41598_020_78266_6 crossref_primary_10_1007_s13311_022_01324_6 crossref_primary_10_1016_j_euroneuro_2024_07_003 crossref_primary_10_1177_0271678X231214443 crossref_primary_10_1016_j_neuroimage_2018_05_017 crossref_primary_10_1016_j_biopsych_2020_01_015 crossref_primary_10_1053_j_semnuclmed_2017_05_001 crossref_primary_10_1007_s00259_021_05269_4 crossref_primary_10_1002_ange_202306019 crossref_primary_10_1016_j_nsa_2023_103929 crossref_primary_10_1002_cpt_2548 crossref_primary_10_1186_s40658_023_00600_4 crossref_primary_10_1021_acs_molpharmaceut_8b00518 crossref_primary_10_1016_j_bmcl_2025_130118 crossref_primary_10_1007_s00213_019_05427_5 crossref_primary_10_1051_jbio_2019025 crossref_primary_10_1098_rsta_2017_0112 crossref_primary_10_3390_molecules24010049 crossref_primary_10_1016_j_drudis_2017_11_012 crossref_primary_10_1177_0271678X231168591 crossref_primary_10_1038_s41386_024_02046_3 crossref_primary_10_1007_s00259_021_05561_3 crossref_primary_10_1080_13543776_2018_1424135 crossref_primary_10_1002_anie_202306019 crossref_primary_10_1038_s41386_019_0324_9 |
| Cites_doi | 10.1016/j.nbd.2013.08.017 10.1038/nrd2027 10.1016/S0006-3223(99)00067-0 10.1038/jcbfm.2010.175 10.1097/00004647-200003000-00001 10.1002/cpt.132 10.1097/00004647-200106000-00002 10.1038/jcbfm.2011.115 10.1016/j.neuroimage.2012.11.033 10.1177/0269881113517953 10.1038/npp.2015.340 10.1124/jpet.112.202895 10.1016/j.drudis.2014.08.012 10.1002/syn.20946 10.1126/scitranslmed.aaf2362 10.1038/jcbfm.2011.147 10.1007/s13346-012-0073-3 10.1001/jamapsychiatry.2014.2414 10.1038/npp.2008.104 10.1038/jcbfm.2012.208 10.1177/026988110201600301 10.2174/0929867323666160418114826 10.1016/j.neuroimage.2009.11.056 10.1001/archpsyc.1988.01800250087012 10.2967/jnumed.115.162248 10.1038/npp.2014.4 10.2967/jnumed.115.160127 10.1016/j.neurobiolaging.2016.04.011 10.1016/j.neuroimage.2016.07.026 10.2967/jnumed.112.111922 10.1088/0031-9155/60/22/R363 10.1016/j.coph.2011.04.009 10.1002/syn.20780 10.1016/S1474-4422(10)70043-0 10.2967/jnumed.109.063800 10.1016/j.drudis.2013.10.007 10.1002/ana.20009 10.1016/j.ddtec.2005.11.003 10.2967/jnumed.114.141713 10.1016/j.biopsych.2015.11.022 10.1007/s40336-015-0147-6 10.1073/pnas.1509667112 10.1038/clpt.2010.9 10.1021/jm400312y 10.1093/brain/aww027 10.1176/ajp.155.6.761 10.1371/journal.pone.0158460 10.1093/brain/awv184 10.1158/1535-7163.MCT-15-0558 10.1097/01.aids.0000432467.54003.f7 10.1017/S1092852913000023 10.1016/j.drudis.2011.12.020 10.1038/jcbfm.2011.55 10.1080/00498250802499459 10.1111/bph.12505 10.1001/jamaneurol.2016.2078 10.1007/BF02244926 10.1038/jcbfm.2012.1 |
| ContentType | Journal Article |
| Copyright | 2017 Elsevier Inc. Elsevier Inc. Copyright © 2017 Elsevier Inc. All rights reserved. |
| Copyright_xml | – notice: 2017 Elsevier Inc. – notice: Elsevier Inc. – notice: Copyright © 2017 Elsevier Inc. All rights reserved. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1053/j.semnuclmed.2016.09.001 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1558-4623 |
| EndPage | 98 |
| ExternalDocumentID | 27987561 10_1053_j_semnuclmed_2016_09_001 S000129981630071X 1_s2_0_S000129981630071X |
| Genre | Journal Article Review |
| GroupedDBID | --- --K --M .1- .55 .FO .GJ .~1 0R~ 123 1B1 1P~ 1RT 1~. 3O- 4.4 457 4CK 4G. 53G 5RE 5VS 7-5 8P~ 8WZ 9JM A6W AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AATTM AAWTL AAXKI AAXUO AAYWO ABBQC ABDPE ABFNM ABFRF ABJNI ABLJU ABMAC ABMZM ABWVN ABXDB ACDAQ ACGFO ACGFS ACIEU ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADMUD ADNMO AEBSH AEFWE AEIPS AEKER AENEX AEUPX AEVXI AFFNX AFJKZ AFPUW AFRHN AFTJW AFXIZ AGCQF AGHFR AGQPQ AGUBO AGYEJ AHHHB AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CS3 DU5 EBS EFJIC EFKBS EJD F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HEI HMK HMO HVGLF HZ~ IHE J1W J5H KOM M27 M41 MO0 N4W N9A NQ- O-L O9- OAUVE OI. OU~ P-8 P-9 P2P PC. Q38 R2- ROL RPZ SAE SDF SEL SES SEW SPCBC SSH SSZ T5K UNMZH WUQ X7M Z5R ZGI ~G- AACTN AFCTW AFKWA AJOXV AMFUW RIG AAIAV ABLVK ABYKQ AHPSJ AJBFU EFLBG G8K LCYCR ZA5 AAYXX AGRNS CITATION CGR CUY CVF ECM EIF NPM 7X8 |
| ID | FETCH-LOGICAL-c486t-d58624ea8c948c9f5e0e171386fda6230af50c070eac6d5de22633cd3d7e84343 |
| IEDL.DBID | .~1 |
| ISSN | 0001-2998 1558-4623 |
| IngestDate | Fri Jul 11 12:03:44 EDT 2025 Wed Feb 19 02:00:08 EST 2025 Thu Apr 24 22:56:49 EDT 2025 Tue Aug 05 11:58:36 EDT 2025 Fri Feb 23 02:34:14 EST 2024 Tue Feb 25 19:54:18 EST 2025 Tue Aug 26 18:43:19 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Language | English |
| License | Copyright © 2017 Elsevier Inc. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c486t-d58624ea8c948c9f5e0e171386fda6230af50c070eac6d5de22633cd3d7e84343 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| PMID | 27987561 |
| PQID | 1851299730 |
| PQPubID | 23479 |
| PageCount | 10 |
| ParticipantIDs | proquest_miscellaneous_1851299730 pubmed_primary_27987561 crossref_citationtrail_10_1053_j_semnuclmed_2016_09_001 crossref_primary_10_1053_j_semnuclmed_2016_09_001 elsevier_sciencedirect_doi_10_1053_j_semnuclmed_2016_09_001 elsevier_clinicalkeyesjournals_1_s2_0_S000129981630071X elsevier_clinicalkey_doi_10_1053_j_semnuclmed_2016_09_001 |
| PublicationCentury | 2000 |
| PublicationDate | January 2017 2017 2017-01-00 2017-Jan 20170101 |
| PublicationDateYYYYMMDD | 2017-01-01 |
| PublicationDate_xml | – month: 01 year: 2017 text: January 2017 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Seminars in nuclear medicine |
| PublicationTitleAlternate | Semin Nucl Med |
| PublicationYear | 2017 |
| Publisher | Elsevier Inc |
| Publisher_xml | – name: Elsevier Inc |
| References | Rabiner, Bhagwagar, Gunn (bib21) 2002; 16 Zamuner, Di Iorio, Nyberg (bib27) 2010; 87 Borsook, Becerra, Hargreaves (bib28) 2006; 5 Lockhart, Baker, Okamura (bib35) 2016; 11 Brier, Gordon, Friedrichsen (bib56) 2016; 8 Hargreaves, Rabiner (bib6) 2014; 61 Cummings, Banks, Gary (bib29) 2013; 18 Zhang, Villalobos, Beck (bib61) 2013; 56 Salinas, Weinzimmer, Searle (bib26) 2013; 33 Altai, Perols, Tsourma (bib16) 2016; 57 Abanades, van der Aart, Barletta (bib25) 2011; 31 Cunningham, Parker, Rabiner (bib7) 2005; 2 Rinne, Brooks, Rossor (bib10) 2010; 9 Hillmer, Esterlis, Gallezot (bib52) 2016; 141 Brooks, Doder, Osman (bib18) 2005; 64 Comley, Salinas, Slifstein (bib20) 2013; 346 Mick, Myers, Ramos (bib50) 2016; 41 Honer, Gobbi, Martarello (bib57) 2014; 19 Frankle, Cho, Narendran (bib53) 2009; 34 Shotbolt, Tziortzi, Searle (bib45) 2012; 32 Owen, Yeo, Gunn (bib43) 2012; 32 Gunn, Slifstein, Searle (bib59) 2015; 60 Finnema, Varrone, Hwang (bib54) 2010; 64 Farde, Wiesel, Halldin (bib4) 1988; 45 Ashworth, Berges, Rabiner (bib17) 2014; 171 Vivash, O’Brien (bib37) 2016; 57 Gunn, Gunn, Cunningham (bib11) 2001; 21 Laruelle (bib32) 2000; 20 Jucaite, Svenningsson, Rinne (bib44) 2015; 138 Morgan, Van Der Graaf, Arrowsmith (bib2) 2012; 17 Slifstein, van de Giessen, Van Snellenberg (bib48) 2015; 72 Klunk, Engler, Nordberg (bib33) 2004; 55 Hargreaves, Hoppin, Sevigny (bib1) 2015; 98 Papisov, Belov, Fischman (bib9) 2012; 2 Rabiner, Gunn, Wilkins (bib22) 2002; 16 Ridler, Gunn, Searle (bib23) 2014; 28 Summerfield, Lucas, Porter (bib13) 2008; 38 Kreisl, Lyoo, Liow (bib40) 2016; 44 Castner, Murthy, Ridler (bib19) 2014; 39 Airas, Rissanen, Rinne (bib38) 2015; 3 Pike (bib58) 2016; 23 Gunn, Summerfield, Salinas (bib12) 2012; 32 Rusjan, Wilson, Bloomfield (bib41) 2011; 31 Garvey, Pavese, Politis (bib30) 2014; 28 Matthews, Rabiner, Gunn (bib8) 2011; 11 Gunn, Rabiner (bib3) 2014; 19 Abi-Dargham, Gil, Krystal (bib46) 1998; 155 Jansen, Lagerweij, Sewing (bib14) 2016; 15 Searle, Beaver, Tziortzi (bib24) 2013; 68 Yokokura, Terada, Bunai (bib42) 2016 Laruelle, Abi-Dargham, Gil (bib47) 1999; 46 Esterlis, Hannestad, Bois (bib51) 2013; 54 Kimura, Ichise, Ito (bib36) 2015; 56 Luo, Hernandez, Hong (bib15) 2015; 112 Ossenkoppele, Schonhaut, Scholl (bib34) 2016; 139 Kreisl, Fujita, Fujimura (bib39) 2010; 49 Bench, Lammertsma, Dolan (bib5) 1993; 112 Ridler, Plisson, Rabiner (bib55) 2011; 65 Wang, Benzinger, Su (bib31) 2016; 73 Colasanti, Guo, Giannetti (bib49) 2016; 80 Guo, Brady, Gunn (bib60) 2009; 50 Jucaite (10.1053/j.semnuclmed.2016.09.001_bib44) 2015; 138 Rabiner (10.1053/j.semnuclmed.2016.09.001_bib22) 2002; 16 Hillmer (10.1053/j.semnuclmed.2016.09.001_bib52) 2016; 141 Brier (10.1053/j.semnuclmed.2016.09.001_bib56) 2016; 8 Gunn (10.1053/j.semnuclmed.2016.09.001_bib11) 2001; 21 Rusjan (10.1053/j.semnuclmed.2016.09.001_bib41) 2011; 31 Yokokura (10.1053/j.semnuclmed.2016.09.001_bib42) 2016 Bench (10.1053/j.semnuclmed.2016.09.001_bib5) 1993; 112 Morgan (10.1053/j.semnuclmed.2016.09.001_bib2) 2012; 17 Slifstein (10.1053/j.semnuclmed.2016.09.001_bib48) 2015; 72 Jansen (10.1053/j.semnuclmed.2016.09.001_bib14) 2016; 15 Ridler (10.1053/j.semnuclmed.2016.09.001_bib23) 2014; 28 Brooks (10.1053/j.semnuclmed.2016.09.001_bib18) 2005; 64 Finnema (10.1053/j.semnuclmed.2016.09.001_bib54) 2010; 64 Castner (10.1053/j.semnuclmed.2016.09.001_bib19) 2014; 39 Rabiner (10.1053/j.semnuclmed.2016.09.001_bib21) 2002; 16 Klunk (10.1053/j.semnuclmed.2016.09.001_bib33) 2004; 55 Wang (10.1053/j.semnuclmed.2016.09.001_bib31) 2016; 73 Mick (10.1053/j.semnuclmed.2016.09.001_bib50) 2016; 41 Papisov (10.1053/j.semnuclmed.2016.09.001_bib9) 2012; 2 Cunningham (10.1053/j.semnuclmed.2016.09.001_bib7) 2005; 2 Pike (10.1053/j.semnuclmed.2016.09.001_bib58) 2016; 23 Laruelle (10.1053/j.semnuclmed.2016.09.001_bib47) 1999; 46 Hargreaves (10.1053/j.semnuclmed.2016.09.001_bib1) 2015; 98 Ashworth (10.1053/j.semnuclmed.2016.09.001_bib17) 2014; 171 Owen (10.1053/j.semnuclmed.2016.09.001_bib43) 2012; 32 Honer (10.1053/j.semnuclmed.2016.09.001_bib57) 2014; 19 Vivash (10.1053/j.semnuclmed.2016.09.001_bib37) 2016; 57 Borsook (10.1053/j.semnuclmed.2016.09.001_bib28) 2006; 5 Ridler (10.1053/j.semnuclmed.2016.09.001_bib55) 2011; 65 Kreisl (10.1053/j.semnuclmed.2016.09.001_bib40) 2016; 44 Shotbolt (10.1053/j.semnuclmed.2016.09.001_bib45) 2012; 32 Matthews (10.1053/j.semnuclmed.2016.09.001_bib8) 2011; 11 Cummings (10.1053/j.semnuclmed.2016.09.001_bib29) 2013; 18 Summerfield (10.1053/j.semnuclmed.2016.09.001_bib13) 2008; 38 Garvey (10.1053/j.semnuclmed.2016.09.001_bib30) 2014; 28 Guo (10.1053/j.semnuclmed.2016.09.001_bib60) 2009; 50 Esterlis (10.1053/j.semnuclmed.2016.09.001_bib51) 2013; 54 Abanades (10.1053/j.semnuclmed.2016.09.001_bib25) 2011; 31 Gunn (10.1053/j.semnuclmed.2016.09.001_bib59) 2015; 60 Laruelle (10.1053/j.semnuclmed.2016.09.001_bib32) 2000; 20 Searle (10.1053/j.semnuclmed.2016.09.001_bib24) 2013; 68 Colasanti (10.1053/j.semnuclmed.2016.09.001_bib49) 2016; 80 Abi-Dargham (10.1053/j.semnuclmed.2016.09.001_bib46) 1998; 155 Zhang (10.1053/j.semnuclmed.2016.09.001_bib61) 2013; 56 Hargreaves (10.1053/j.semnuclmed.2016.09.001_bib6) 2014; 61 Frankle (10.1053/j.semnuclmed.2016.09.001_bib53) 2009; 34 Gunn (10.1053/j.semnuclmed.2016.09.001_bib12) 2012; 32 Kreisl (10.1053/j.semnuclmed.2016.09.001_bib39) 2010; 49 Rinne (10.1053/j.semnuclmed.2016.09.001_bib10) 2010; 9 Zamuner (10.1053/j.semnuclmed.2016.09.001_bib27) 2010; 87 Lockhart (10.1053/j.semnuclmed.2016.09.001_bib35) 2016; 11 Kimura (10.1053/j.semnuclmed.2016.09.001_bib36) 2015; 56 Luo (10.1053/j.semnuclmed.2016.09.001_bib15) 2015; 112 Airas (10.1053/j.semnuclmed.2016.09.001_bib38) 2015; 3 Gunn (10.1053/j.semnuclmed.2016.09.001_bib3) 2014; 19 Comley (10.1053/j.semnuclmed.2016.09.001_bib20) 2013; 346 Ossenkoppele (10.1053/j.semnuclmed.2016.09.001_bib34) 2016; 139 Altai (10.1053/j.semnuclmed.2016.09.001_bib16) 2016; 57 Farde (10.1053/j.semnuclmed.2016.09.001_bib4) 1988; 45 Salinas (10.1053/j.semnuclmed.2016.09.001_bib26) 2013; 33 |
| References_xml | – volume: 45 start-page: 71 year: 1988 end-page: 76 ident: bib4 article-title: Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs publication-title: Arch Gen Psychiatry – volume: 21 start-page: 635 year: 2001 end-page: 652 ident: bib11 article-title: Positron emission tomography compartmental models publication-title: J Cereb Blood Flow Metab – year: 2016 ident: bib42 article-title: Depiction of microglial activation in aging and dementia: Positron emission tomography with [11C]DPA713 versus [11C](R)PK11195 publication-title: J Cereb Blood Flow Metab – volume: 32 start-page: 127 year: 2012 end-page: 136 ident: bib45 article-title: Within-subject comparison of [(11)C]-(+)-PHNO and [(11)C]raclopride sensitivity to acute amphetamine challenge in healthy humans publication-title: J Cereb Blood Flow Metab – volume: 15 start-page: 2166 year: 2016 end-page: 2174 ident: bib14 article-title: Bevacizumab targeting diffuse intrinsic pontine glioma: Results of 89Zr-bevacizumab PET imaging in brain tumor models publication-title: Mol Cancer Ther – volume: 31 start-page: 1807 year: 2011 end-page: 1816 ident: bib41 article-title: Quantitation of translocator protein binding in human brain with the novel radioligand [18F]-FEPPA and positron emission tomography publication-title: J Cereb Blood Flow Metab – volume: 155 start-page: 761 year: 1998 end-page: 767 ident: bib46 article-title: Increased striatal dopamine transmission in schizophrenia: Confirmation in a second cohort publication-title: Am J Psychiatry – volume: 9 start-page: 363 year: 2010 end-page: 372 ident: bib10 article-title: 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer’s disease treated with bapineuzumab: A Phase 2, double-blind, placebo-controlled, ascending-dose study publication-title: Lancet Neurol – volume: 60 start-page: R363 year: 2015 end-page: R411 ident: bib59 article-title: Quantitative imaging of protein targets in the human brain with PET publication-title: Phys Med Biol – volume: 87 start-page: 563 year: 2010 end-page: 571 ident: bib27 article-title: Adaptive-optimal design in PET occupancy studies publication-title: Clin Pharmacol Ther – volume: 38 start-page: 1518 year: 2008 end-page: 1535 ident: bib13 article-title: Toward an improved prediction of human in vivo brain penetration publication-title: Xenobiotica – volume: 139 start-page: 1551 year: 2016 end-page: 1567 ident: bib34 article-title: Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer’s disease publication-title: Brain – volume: 23 start-page: 1818 year: 2016 end-page: 1869 ident: bib58 article-title: Considerations in the development of reversibly binding PET radioligands for brain imaging publication-title: Curr Med Chem – volume: 19 start-page: 1936 year: 2014 end-page: 1944 ident: bib57 article-title: Radioligand development for molecular imaging of the central nervous system with positron emission tomography publication-title: Drug Discov Today – volume: 28 start-page: 244 year: 2014 end-page: 253 ident: bib23 article-title: Characterising the plasma-target occupancy relationship of the neurokinin antagonist GSK1144814 with PET publication-title: J Psychopharmacol – volume: 57 start-page: 165 year: 2016 end-page: 168 ident: bib37 article-title: Imaging microglial activation with TSPO PET: Lighting up neurologic diseases? publication-title: J Nucl Med – volume: 61 start-page: 32 year: 2014 end-page: 38 ident: bib6 article-title: Translational PET imaging research publication-title: Neurobiol Dis – volume: 5 start-page: 411 year: 2006 end-page: 424 ident: bib28 article-title: A role for fMRI in optimizing CNS drug development publication-title: Nat Rev Drug Discov – volume: 98 start-page: 47 year: 2015 end-page: 60 ident: bib1 article-title: Optimizing central nervous system drug development using molecular imaging publication-title: Clin Pharmacol Ther – volume: 33 start-page: 700 year: 2013 end-page: 707 ident: bib26 article-title: Kinetic analysis of drug-target interactions with PET for characterization of pharmacological hysteresis publication-title: J Cereb Blood Flow Metab – volume: 50 start-page: 1715 year: 2009 end-page: 1723 ident: bib60 article-title: A biomathematical modeling approach to central nervous system radioligand discovery and development publication-title: J Nucl Med – volume: 80 start-page: 62 year: 2016 end-page: 72 ident: bib49 article-title: Hippocampal neuroinflammation, functional connectivity, and depressive symptoms in multiple sclerosis publication-title: Biol Psychiatry – volume: 32 start-page: 1 year: 2012 end-page: 5 ident: bib43 article-title: An 18-kDa translocator protein (TSPO) polymorphism explains differences in binding affinity of the PET radioligand PBR28 publication-title: J Cereb Blood Flow Metab – volume: 65 start-page: 1119 year: 2011 end-page: 1127 ident: bib55 article-title: Characterization of in vivo pharmacological properties and sensitivity to endogenous serotonin of [11C] P943: A positron emission tomography study in Papio anubis publication-title: Synapse – volume: 73 start-page: 1070 year: 2016 end-page: 1077 ident: bib31 article-title: Evaluation of tau imaging in staging alzheimer disease and revealing interactions between beta-amyloid and tauopathy publication-title: JAMA Neurol – volume: 64 start-page: 573 year: 2010 end-page: 577 ident: bib54 article-title: Fenfluramine-induced serotonin release decreases [11C]AZ10419369 binding to 5-HT1B-receptors in the primate brain publication-title: Synapse – volume: 49 start-page: 2924 year: 2010 end-page: 2932 ident: bib39 article-title: Comparison of [(11)C]-(R)-PK 11195 and [(11)C]PBR28, two radioligands for translocator protein (18 publication-title: Neuroimage – volume: 112 start-page: 308 year: 1993 end-page: 314 ident: bib5 article-title: Dose dependent occupancy of central dopamine D2 receptors by the novel neuroleptic CP-88,059-01: A study using positron emission tomography and 11C-raclopride publication-title: Psychopharmacology – volume: 41 start-page: 1742 year: 2016 end-page: 1750 ident: bib50 article-title: Blunted endogenous opioid release following an oral amphetamine challenge in pathological gamblers publication-title: Neuropsychopharmacology – volume: 17 start-page: 419 year: 2012 end-page: 424 ident: bib2 article-title: Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival publication-title: Drug Discov Today – volume: 64 year: 2005 ident: bib18 article-title: Adenosine A(2A) receptor occupancy by istradefylline. An C-11 KW-6002 PET study in healthy subjects publication-title: Neurology – volume: 112 start-page: 12806 year: 2015 end-page: 12811 ident: bib15 article-title: Noninvasive brain cancer imaging with a bispecific antibody fragment, generated via click chemistry publication-title: Proc Natl Acad Sci U S A – volume: 3 start-page: 461 year: 2015 end-page: 473 ident: bib38 article-title: Imaging neuroinflammation in multiple sclerosis using TSPO-PET publication-title: Clin Transl Imaging – volume: 138 start-page: 2687 year: 2015 end-page: 2700 ident: bib44 article-title: Effect of the myeloperoxidase inhibitor AZD3241 on microglia: A PET study in Parkinson’s disease publication-title: Brain – volume: 56 start-page: 4568 year: 2013 end-page: 4579 ident: bib61 article-title: Design and selection parameters to accelerate the discovery of novel central nervous system positron emission tomography (PET) ligands and their application in the development of a novel phosphodiesterase 2A PET ligand publication-title: J Med Chem – volume: 18 start-page: 128 year: 2013 end-page: 138 ident: bib29 article-title: Alzheimer’s disease drug development: Translational neuroscience strategies publication-title: CNS Spectr – volume: 68 start-page: 119 year: 2013 end-page: 132 ident: bib24 article-title: Mathematical modelling of [(1)(1)C]-(+)-PHNO human competition studies publication-title: Neuroimage – volume: 46 start-page: 56 year: 1999 end-page: 72 ident: bib47 article-title: Increased dopamine transmission in schizophrenia: Relationship to illness phases publication-title: Biol Psychiatry – volume: 72 start-page: 316 year: 2015 end-page: 324 ident: bib48 article-title: Deficits in prefrontal cortical and extrastriatal dopamine release in schizophrenia: A positron emission tomographic functional magnetic resonance imaging study publication-title: JAMA Psychiatry – volume: 44 start-page: 53 year: 2016 end-page: 61 ident: bib40 article-title: (11)C-PBR28 binding to translocator protein increases with progression of Alzheimer’s disease publication-title: Neurobiol Aging – volume: 55 start-page: 306 year: 2004 end-page: 319 ident: bib33 article-title: Imaging brain amyloid in Alzheimer’s disease with Pittsburgh compound-B publication-title: Ann Neurol – volume: 8 start-page: 338ra66 year: 2016 ident: bib56 article-title: Tau and Abeta imaging, CSF measures, and cognition in Alzheimer’s disease publication-title: Sci Transl Med – volume: 32 start-page: 874 year: 2012 end-page: 883 ident: bib12 article-title: Combining PET biodistribution and equilibrium dialysis assays to assess the free brain concentration and BBB transport of CNS drugs publication-title: J Cereb Blood Flow Metab – volume: 141 start-page: 71 year: 2016 end-page: 80 ident: bib52 article-title: Imaging of cerebral alpha4beta2* nicotinic acetylcholine receptors with (-)-[18F]Flubatine PET: Implementation of bolus plus constant infusion and sensitivity to acetylcholine in human brain publication-title: Neuroimage – volume: 20 start-page: 423 year: 2000 end-page: 451 ident: bib32 article-title: Imaging synaptic neurotransmission with in vivo binding competition techniques: A critical review publication-title: J Cereb Blood Flow Metab – volume: 19 start-page: 1 year: 2014 end-page: 3 ident: bib3 article-title: Making drug development visible—And viable publication-title: Drug Discov Today – volume: 16 start-page: 195 year: 2002 end-page: 199 ident: bib22 article-title: Evaluation of EMD 128 130 occupancy of the 5-HT1A and the D-2 receptor: A human PET study with C-11 WAY-100635 and C-11 raclopride publication-title: J Psychopharmacol – volume: 57 start-page: 431 year: 2016 end-page: 436 ident: bib16 article-title: Feasibility of affibody-based bioorthogonal chemistry-mediated radionuclide pretargeting publication-title: J Nucl Med – volume: 11 start-page: 501 year: 2011 end-page: 507 ident: bib8 article-title: Non-invasive imaging in experimental medicine for drug development publication-title: Curr Opin Pharmacol – volume: 346 start-page: 311 year: 2013 end-page: 317 ident: bib20 article-title: Monoamine transporter occupancy of a novel triple reuptake inhibitor in baboons and humans using positron emission tomography publication-title: J Pharmacol Exp Ther – volume: 11 start-page: e0158460 year: 2016 ident: bib35 article-title: Dynamic PET measures of tau accumulation in cognitively normal older adults and Alzheimer’s disease patients measured using [18F] THK-5351 publication-title: PLoS One – volume: 54 start-page: 78 year: 2013 end-page: 82 ident: bib51 article-title: Imaging changes in synaptic acetylcholine availability in living human subjects publication-title: J Nucl Med – volume: 56 start-page: 1359 year: 2015 end-page: 1365 ident: bib36 article-title: PET quantification of tau pathology in human brain with 11C-PBB3 publication-title: J Nucl Med – volume: 2 start-page: 311 year: 2005 end-page: 315 ident: bib7 article-title: PET studies in drug development: Methodological considerations publication-title: Drug Discov Today Technol – volume: 16 year: 2002 ident: bib21 article-title: Attenuation of preferential occupancy of 5-HT1A autoreceptors by pindolol in depressed patients: Effect of SSRIs or an endophenotype of the depressed state publication-title: Neuroimage – volume: 31 start-page: 944 year: 2011 end-page: 952 ident: bib25 article-title: Prediction of repeat-dose occupancy from single-dose data: Characterisation of the relationship between plasma pharmacokinetics and brain target occupancy publication-title: J Cereb Blood Flow Metab – volume: 28 start-page: 67 year: 2014 end-page: 72 ident: bib30 article-title: Increased microglia activation in neurologically asymptomatic HIV-infected patients receiving effective ART publication-title: AIDS – volume: 34 start-page: 624 year: 2009 end-page: 633 ident: bib53 article-title: Tiagabine increases [11C]flumazenil binding in cortical brain regions in healthy control subjects publication-title: Neuropsychopharmacology – volume: 39 start-page: 2742 year: 2014 end-page: 2749 ident: bib19 article-title: Relationship between glycine transporter 1 inhibition as measured with positron emission tomography and changes in cognitive performances in nonhuman primates publication-title: Neuropsychopharmacology – volume: 171 start-page: 1241 year: 2014 end-page: 1249 ident: bib17 article-title: Unexpectedly high affinity of a novel histamine H(3) receptor antagonist, GSK239512, in vivo in human brain, determined using PET publication-title: Br J Pharmacol – volume: 2 start-page: 201 year: 2012 end-page: 209 ident: bib9 article-title: Delivery of proteins to CNS as seen and measured by positron emission tomography publication-title: Drug Deliv Transl Res – volume: 61 start-page: 32 year: 2014 ident: 10.1053/j.semnuclmed.2016.09.001_bib6 article-title: Translational PET imaging research publication-title: Neurobiol Dis doi: 10.1016/j.nbd.2013.08.017 – volume: 5 start-page: 411 year: 2006 ident: 10.1053/j.semnuclmed.2016.09.001_bib28 article-title: A role for fMRI in optimizing CNS drug development publication-title: Nat Rev Drug Discov doi: 10.1038/nrd2027 – volume: 46 start-page: 56 year: 1999 ident: 10.1053/j.semnuclmed.2016.09.001_bib47 article-title: Increased dopamine transmission in schizophrenia: Relationship to illness phases publication-title: Biol Psychiatry doi: 10.1016/S0006-3223(99)00067-0 – volume: 31 start-page: 944 year: 2011 ident: 10.1053/j.semnuclmed.2016.09.001_bib25 article-title: Prediction of repeat-dose occupancy from single-dose data: Characterisation of the relationship between plasma pharmacokinetics and brain target occupancy publication-title: J Cereb Blood Flow Metab doi: 10.1038/jcbfm.2010.175 – volume: 20 start-page: 423 year: 2000 ident: 10.1053/j.semnuclmed.2016.09.001_bib32 article-title: Imaging synaptic neurotransmission with in vivo binding competition techniques: A critical review publication-title: J Cereb Blood Flow Metab doi: 10.1097/00004647-200003000-00001 – volume: 98 start-page: 47 year: 2015 ident: 10.1053/j.semnuclmed.2016.09.001_bib1 article-title: Optimizing central nervous system drug development using molecular imaging publication-title: Clin Pharmacol Ther doi: 10.1002/cpt.132 – volume: 21 start-page: 635 year: 2001 ident: 10.1053/j.semnuclmed.2016.09.001_bib11 article-title: Positron emission tomography compartmental models publication-title: J Cereb Blood Flow Metab doi: 10.1097/00004647-200106000-00002 – volume: 32 start-page: 127 year: 2012 ident: 10.1053/j.semnuclmed.2016.09.001_bib45 article-title: Within-subject comparison of [(11)C]-(+)-PHNO and [(11)C]raclopride sensitivity to acute amphetamine challenge in healthy humans publication-title: J Cereb Blood Flow Metab doi: 10.1038/jcbfm.2011.115 – volume: 68 start-page: 119 year: 2013 ident: 10.1053/j.semnuclmed.2016.09.001_bib24 article-title: Mathematical modelling of [(1)(1)C]-(+)-PHNO human competition studies publication-title: Neuroimage doi: 10.1016/j.neuroimage.2012.11.033 – volume: 28 start-page: 244 year: 2014 ident: 10.1053/j.semnuclmed.2016.09.001_bib23 article-title: Characterising the plasma-target occupancy relationship of the neurokinin antagonist GSK1144814 with PET publication-title: J Psychopharmacol doi: 10.1177/0269881113517953 – volume: 41 start-page: 1742 year: 2016 ident: 10.1053/j.semnuclmed.2016.09.001_bib50 article-title: Blunted endogenous opioid release following an oral amphetamine challenge in pathological gamblers publication-title: Neuropsychopharmacology doi: 10.1038/npp.2015.340 – volume: 346 start-page: 311 year: 2013 ident: 10.1053/j.semnuclmed.2016.09.001_bib20 article-title: Monoamine transporter occupancy of a novel triple reuptake inhibitor in baboons and humans using positron emission tomography publication-title: J Pharmacol Exp Ther doi: 10.1124/jpet.112.202895 – volume: 19 start-page: 1936 year: 2014 ident: 10.1053/j.semnuclmed.2016.09.001_bib57 article-title: Radioligand development for molecular imaging of the central nervous system with positron emission tomography publication-title: Drug Discov Today doi: 10.1016/j.drudis.2014.08.012 – volume: 16 year: 2002 ident: 10.1053/j.semnuclmed.2016.09.001_bib21 article-title: Attenuation of preferential occupancy of 5-HT1A autoreceptors by pindolol in depressed patients: Effect of SSRIs or an endophenotype of the depressed state? publication-title: Neuroimage – volume: 65 start-page: 1119 year: 2011 ident: 10.1053/j.semnuclmed.2016.09.001_bib55 article-title: Characterization of in vivo pharmacological properties and sensitivity to endogenous serotonin of [11C] P943: A positron emission tomography study in Papio anubis publication-title: Synapse doi: 10.1002/syn.20946 – volume: 8 start-page: 338ra66 year: 2016 ident: 10.1053/j.semnuclmed.2016.09.001_bib56 article-title: Tau and Abeta imaging, CSF measures, and cognition in Alzheimer’s disease publication-title: Sci Transl Med doi: 10.1126/scitranslmed.aaf2362 – volume: 32 start-page: 1 year: 2012 ident: 10.1053/j.semnuclmed.2016.09.001_bib43 article-title: An 18-kDa translocator protein (TSPO) polymorphism explains differences in binding affinity of the PET radioligand PBR28 publication-title: J Cereb Blood Flow Metab doi: 10.1038/jcbfm.2011.147 – volume: 2 start-page: 201 year: 2012 ident: 10.1053/j.semnuclmed.2016.09.001_bib9 article-title: Delivery of proteins to CNS as seen and measured by positron emission tomography publication-title: Drug Deliv Transl Res doi: 10.1007/s13346-012-0073-3 – volume: 72 start-page: 316 year: 2015 ident: 10.1053/j.semnuclmed.2016.09.001_bib48 article-title: Deficits in prefrontal cortical and extrastriatal dopamine release in schizophrenia: A positron emission tomographic functional magnetic resonance imaging study publication-title: JAMA Psychiatry doi: 10.1001/jamapsychiatry.2014.2414 – volume: 34 start-page: 624 year: 2009 ident: 10.1053/j.semnuclmed.2016.09.001_bib53 article-title: Tiagabine increases [11C]flumazenil binding in cortical brain regions in healthy control subjects publication-title: Neuropsychopharmacology doi: 10.1038/npp.2008.104 – volume: 33 start-page: 700 year: 2013 ident: 10.1053/j.semnuclmed.2016.09.001_bib26 article-title: Kinetic analysis of drug-target interactions with PET for characterization of pharmacological hysteresis publication-title: J Cereb Blood Flow Metab doi: 10.1038/jcbfm.2012.208 – volume: 16 start-page: 195 year: 2002 ident: 10.1053/j.semnuclmed.2016.09.001_bib22 article-title: Evaluation of EMD 128 130 occupancy of the 5-HT1A and the D-2 receptor: A human PET study with C-11 WAY-100635 and C-11 raclopride publication-title: J Psychopharmacol doi: 10.1177/026988110201600301 – volume: 23 start-page: 1818 year: 2016 ident: 10.1053/j.semnuclmed.2016.09.001_bib58 article-title: Considerations in the development of reversibly binding PET radioligands for brain imaging publication-title: Curr Med Chem doi: 10.2174/0929867323666160418114826 – volume: 49 start-page: 2924 year: 2010 ident: 10.1053/j.semnuclmed.2016.09.001_bib39 article-title: Comparison of [(11)C]-(R)-PK 11195 and [(11)C]PBR28, two radioligands for translocator protein (18kDa) in human and monkey: Implications for positron emission tomographic imaging of this inflammation biomarker publication-title: Neuroimage doi: 10.1016/j.neuroimage.2009.11.056 – volume: 45 start-page: 71 year: 1988 ident: 10.1053/j.semnuclmed.2016.09.001_bib4 article-title: Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs publication-title: Arch Gen Psychiatry doi: 10.1001/archpsyc.1988.01800250087012 – volume: 57 start-page: 431 year: 2016 ident: 10.1053/j.semnuclmed.2016.09.001_bib16 article-title: Feasibility of affibody-based bioorthogonal chemistry-mediated radionuclide pretargeting publication-title: J Nucl Med doi: 10.2967/jnumed.115.162248 – volume: 39 start-page: 2742 year: 2014 ident: 10.1053/j.semnuclmed.2016.09.001_bib19 article-title: Relationship between glycine transporter 1 inhibition as measured with positron emission tomography and changes in cognitive performances in nonhuman primates publication-title: Neuropsychopharmacology doi: 10.1038/npp.2014.4 – volume: 56 start-page: 1359 year: 2015 ident: 10.1053/j.semnuclmed.2016.09.001_bib36 article-title: PET quantification of tau pathology in human brain with 11C-PBB3 publication-title: J Nucl Med doi: 10.2967/jnumed.115.160127 – volume: 44 start-page: 53 year: 2016 ident: 10.1053/j.semnuclmed.2016.09.001_bib40 article-title: (11)C-PBR28 binding to translocator protein increases with progression of Alzheimer’s disease publication-title: Neurobiol Aging doi: 10.1016/j.neurobiolaging.2016.04.011 – volume: 141 start-page: 71 year: 2016 ident: 10.1053/j.semnuclmed.2016.09.001_bib52 article-title: Imaging of cerebral alpha4beta2* nicotinic acetylcholine receptors with (-)-[18F]Flubatine PET: Implementation of bolus plus constant infusion and sensitivity to acetylcholine in human brain publication-title: Neuroimage doi: 10.1016/j.neuroimage.2016.07.026 – volume: 54 start-page: 78 year: 2013 ident: 10.1053/j.semnuclmed.2016.09.001_bib51 article-title: Imaging changes in synaptic acetylcholine availability in living human subjects publication-title: J Nucl Med doi: 10.2967/jnumed.112.111922 – volume: 60 start-page: R363 year: 2015 ident: 10.1053/j.semnuclmed.2016.09.001_bib59 article-title: Quantitative imaging of protein targets in the human brain with PET publication-title: Phys Med Biol doi: 10.1088/0031-9155/60/22/R363 – volume: 11 start-page: 501 year: 2011 ident: 10.1053/j.semnuclmed.2016.09.001_bib8 article-title: Non-invasive imaging in experimental medicine for drug development publication-title: Curr Opin Pharmacol doi: 10.1016/j.coph.2011.04.009 – volume: 64 start-page: 573 year: 2010 ident: 10.1053/j.semnuclmed.2016.09.001_bib54 article-title: Fenfluramine-induced serotonin release decreases [11C]AZ10419369 binding to 5-HT1B-receptors in the primate brain publication-title: Synapse doi: 10.1002/syn.20780 – volume: 9 start-page: 363 year: 2010 ident: 10.1053/j.semnuclmed.2016.09.001_bib10 article-title: 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer’s disease treated with bapineuzumab: A Phase 2, double-blind, placebo-controlled, ascending-dose study publication-title: Lancet Neurol doi: 10.1016/S1474-4422(10)70043-0 – volume: 50 start-page: 1715 year: 2009 ident: 10.1053/j.semnuclmed.2016.09.001_bib60 article-title: A biomathematical modeling approach to central nervous system radioligand discovery and development publication-title: J Nucl Med doi: 10.2967/jnumed.109.063800 – volume: 19 start-page: 1 year: 2014 ident: 10.1053/j.semnuclmed.2016.09.001_bib3 article-title: Making drug development visible—And viable publication-title: Drug Discov Today doi: 10.1016/j.drudis.2013.10.007 – volume: 55 start-page: 306 year: 2004 ident: 10.1053/j.semnuclmed.2016.09.001_bib33 article-title: Imaging brain amyloid in Alzheimer’s disease with Pittsburgh compound-B publication-title: Ann Neurol doi: 10.1002/ana.20009 – volume: 2 start-page: 311 year: 2005 ident: 10.1053/j.semnuclmed.2016.09.001_bib7 article-title: PET studies in drug development: Methodological considerations publication-title: Drug Discov Today Technol doi: 10.1016/j.ddtec.2005.11.003 – volume: 57 start-page: 165 year: 2016 ident: 10.1053/j.semnuclmed.2016.09.001_bib37 article-title: Imaging microglial activation with TSPO PET: Lighting up neurologic diseases? publication-title: J Nucl Med doi: 10.2967/jnumed.114.141713 – volume: 80 start-page: 62 year: 2016 ident: 10.1053/j.semnuclmed.2016.09.001_bib49 article-title: Hippocampal neuroinflammation, functional connectivity, and depressive symptoms in multiple sclerosis publication-title: Biol Psychiatry doi: 10.1016/j.biopsych.2015.11.022 – volume: 3 start-page: 461 year: 2015 ident: 10.1053/j.semnuclmed.2016.09.001_bib38 article-title: Imaging neuroinflammation in multiple sclerosis using TSPO-PET publication-title: Clin Transl Imaging doi: 10.1007/s40336-015-0147-6 – volume: 112 start-page: 12806 year: 2015 ident: 10.1053/j.semnuclmed.2016.09.001_bib15 article-title: Noninvasive brain cancer imaging with a bispecific antibody fragment, generated via click chemistry publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.1509667112 – volume: 87 start-page: 563 year: 2010 ident: 10.1053/j.semnuclmed.2016.09.001_bib27 article-title: Adaptive-optimal design in PET occupancy studies publication-title: Clin Pharmacol Ther doi: 10.1038/clpt.2010.9 – volume: 56 start-page: 4568 year: 2013 ident: 10.1053/j.semnuclmed.2016.09.001_bib61 article-title: Design and selection parameters to accelerate the discovery of novel central nervous system positron emission tomography (PET) ligands and their application in the development of a novel phosphodiesterase 2A PET ligand publication-title: J Med Chem doi: 10.1021/jm400312y – volume: 139 start-page: 1551 year: 2016 ident: 10.1053/j.semnuclmed.2016.09.001_bib34 article-title: Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer’s disease publication-title: Brain doi: 10.1093/brain/aww027 – volume: 155 start-page: 761 year: 1998 ident: 10.1053/j.semnuclmed.2016.09.001_bib46 article-title: Increased striatal dopamine transmission in schizophrenia: Confirmation in a second cohort publication-title: Am J Psychiatry doi: 10.1176/ajp.155.6.761 – volume: 11 start-page: e0158460 year: 2016 ident: 10.1053/j.semnuclmed.2016.09.001_bib35 article-title: Dynamic PET measures of tau accumulation in cognitively normal older adults and Alzheimer’s disease patients measured using [18F] THK-5351 publication-title: PLoS One doi: 10.1371/journal.pone.0158460 – volume: 138 start-page: 2687 year: 2015 ident: 10.1053/j.semnuclmed.2016.09.001_bib44 article-title: Effect of the myeloperoxidase inhibitor AZD3241 on microglia: A PET study in Parkinson’s disease publication-title: Brain doi: 10.1093/brain/awv184 – volume: 15 start-page: 2166 year: 2016 ident: 10.1053/j.semnuclmed.2016.09.001_bib14 article-title: Bevacizumab targeting diffuse intrinsic pontine glioma: Results of 89Zr-bevacizumab PET imaging in brain tumor models publication-title: Mol Cancer Ther doi: 10.1158/1535-7163.MCT-15-0558 – volume: 28 start-page: 67 year: 2014 ident: 10.1053/j.semnuclmed.2016.09.001_bib30 article-title: Increased microglia activation in neurologically asymptomatic HIV-infected patients receiving effective ART publication-title: AIDS doi: 10.1097/01.aids.0000432467.54003.f7 – volume: 18 start-page: 128 year: 2013 ident: 10.1053/j.semnuclmed.2016.09.001_bib29 article-title: Alzheimer’s disease drug development: Translational neuroscience strategies publication-title: CNS Spectr doi: 10.1017/S1092852913000023 – volume: 17 start-page: 419 year: 2012 ident: 10.1053/j.semnuclmed.2016.09.001_bib2 article-title: Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival publication-title: Drug Discov Today doi: 10.1016/j.drudis.2011.12.020 – volume: 64 year: 2005 ident: 10.1053/j.semnuclmed.2016.09.001_bib18 article-title: Adenosine A(2A) receptor occupancy by istradefylline. An C-11 KW-6002 PET study in healthy subjects publication-title: Neurology – volume: 31 start-page: 1807 year: 2011 ident: 10.1053/j.semnuclmed.2016.09.001_bib41 article-title: Quantitation of translocator protein binding in human brain with the novel radioligand [18F]-FEPPA and positron emission tomography publication-title: J Cereb Blood Flow Metab doi: 10.1038/jcbfm.2011.55 – volume: 38 start-page: 1518 year: 2008 ident: 10.1053/j.semnuclmed.2016.09.001_bib13 article-title: Toward an improved prediction of human in vivo brain penetration publication-title: Xenobiotica doi: 10.1080/00498250802499459 – volume: 171 start-page: 1241 year: 2014 ident: 10.1053/j.semnuclmed.2016.09.001_bib17 article-title: Unexpectedly high affinity of a novel histamine H(3) receptor antagonist, GSK239512, in vivo in human brain, determined using PET publication-title: Br J Pharmacol doi: 10.1111/bph.12505 – volume: 73 start-page: 1070 year: 2016 ident: 10.1053/j.semnuclmed.2016.09.001_bib31 article-title: Evaluation of tau imaging in staging alzheimer disease and revealing interactions between beta-amyloid and tauopathy publication-title: JAMA Neurol doi: 10.1001/jamaneurol.2016.2078 – volume: 112 start-page: 308 year: 1993 ident: 10.1053/j.semnuclmed.2016.09.001_bib5 article-title: Dose dependent occupancy of central dopamine D2 receptors by the novel neuroleptic CP-88,059-01: A study using positron emission tomography and 11C-raclopride publication-title: Psychopharmacology doi: 10.1007/BF02244926 – volume: 32 start-page: 874 year: 2012 ident: 10.1053/j.semnuclmed.2016.09.001_bib12 article-title: Combining PET biodistribution and equilibrium dialysis assays to assess the free brain concentration and BBB transport of CNS drugs publication-title: J Cereb Blood Flow Metab doi: 10.1038/jcbfm.2012.1 – year: 2016 ident: 10.1053/j.semnuclmed.2016.09.001_bib42 article-title: Depiction of microglial activation in aging and dementia: Positron emission tomography with [11C]DPA713 versus [11C](R)PK11195 publication-title: J Cereb Blood Flow Metab |
| SSID | ssj0025595 |
| Score | 2.3414805 |
| SecondaryResourceType | review_article |
| Snippet | The discovery and development of central nervous system (CNS) drugs is an extremely challenging process requiring large resources, timelines, and associated... |
| SourceID | proquest pubmed crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 89 |
| SubjectTerms | Biomarkers - metabolism Central Nervous System Agents - metabolism Central Nervous System Agents - pharmacokinetics Central Nervous System Agents - pharmacology Drug Discovery - methods Humans Molecular Targeted Therapy Positron-Emission Tomography - methods Radiology Tissue Distribution |
| Title | Imaging in Central Nervous System Drug Discovery |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S000129981630071X https://www.clinicalkey.es/playcontent/1-s2.0-S000129981630071X https://dx.doi.org/10.1053/j.semnuclmed.2016.09.001 https://www.ncbi.nlm.nih.gov/pubmed/27987561 https://www.proquest.com/docview/1851299730 |
| Volume | 47 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3Na8IwFA_iYOwy9j33IR3sWk3apk3ZSXSiG_M0wVuIaToE7cSPwy772_demzrGJgg7tIfaR8rz5ZffS94HIfec-UADKHU9LagbKD12hY6Mm4Z8nHCmtZ_mAbKDsDcMnkZ8VCHtMhcGwyot9heYnqO1fdK02mzOJxPM8cVNlFgwrBoVsRFmsAcRWnnjcxPmgYy56GIAbjO-baN5wPaamNU9y9Z6CusOBnmFjaJ45bYlahsFzZei7hE5tBzSaRWfeUwqJjsh-y_2lPyU0P4s7z3kTDLH7t46A8AEcPKdokK501ms35zOZKkxgvPjjAy7j6_tnms7I7g6EOHKTTjmdRgldBzAlXJDDQN3U4RpooDQUJVyqmE2A6yGCU8MkCzf14mfREZgLuk5qWbvmbnEnG0mjPF9T2n4hY0VFbESnoIb00kY1UhUKkNqWzYcu1dMZX58zX1wH77VKFGNksYYKlcjbCM5L0pn7CATl_qWZWoogJkEfN9BNvpL1iztrFxKJpeepPKX5dTIw0byh_HtOO5daRgS5iYeuKjMwF8qgQvhOACiNXJRWMxGE14Ug6sYsqt_jX1NDjzkGfme0A2prhZrcwssaTWu59OgTvZa_efe4AueuxEf |
| linkProvider | Elsevier |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3PT9swFH4CJg0uiDEYZTAyaRxD7SROHE0cEB1qB_QEUm_GdZypUgmItEJc-Kf4B3kvcYomhlRp4pAeUr26en7-_D37_QD4IXiINIAxPzCS-ZE2Q1-axPp5LIaZ4MaEeRUg24-7l9HvgRgswFOTC0NhlQ77a0yv0Nq9aTtttm9HI8rxpUOUVHKqGpXwgYusPLUP9-i3lYe9Dk7yfhCc_Lo47vqutYBvIhlP_ExQYoTV0qQRPrmwzHL012ScZxoZAdO5YAaXA-JSnInMIksJQ5OFWWIlJWPi7y7ChwjhgtomHDzO4kqIotdtE9BPp7_nwofQ2NuURn5dTM0YNzqKKosP6mqZb-2Jb3Heau87WYNVR1q9o1ovn2DBFuvw8dxdy38G1ruumh15o8Jzx8VeH0HoZlp6dUl0r3M3_eN1RqWhkNGHDbh8F31twlJxU9gtShLn0towDLTBb_hQM5lqGWj84CaLkxYkjTKUcXXKqV3GWFX35SJEf-VFjYrUqFhKsXkt4DPJ27pWxxwyaaNv1eSiInoq3FDmkE3-JWtLBwOl4qoMFFOvTLUFP2eSf1n7nON-bwxDIRjQDY8uLE6pQvJF4yBqt-BLbTEzTQRJir5pzLf_a-w9WO5enJ-ps17_9CusBERyqgOpHVia3E3tLlK0yfBbtSQ8uHrvNfgMvP9Mlw |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Imaging+in+Central+Nervous+System+Drug+Discovery&rft.jtitle=Seminars+in+nuclear+medicine&rft.au=Gunn%2C+Roger+N.%2C+PhD&rft.au=Rabiner%2C+Eugenii+A.%2C+FCPsych+%28SA%29&rft.date=2017&rft.issn=0001-2998&rft.volume=47&rft.issue=1&rft.spage=89&rft.epage=98&rft_id=info:doi/10.1053%2Fj.semnuclmed.2016.09.001&rft.externalDBID=ECK1-s2.0-S000129981630071X&rft.externalDocID=1_s2_0_S000129981630071X |
| thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F00012998%2FS0001299816X00074%2Fcov150h.gif |